Test report 2020

Due to the fact that TP2 microelements demonstrate an effect on the treatment of cancers, which has been confirmed by the testimonies of many people, the decision was made to conduct laboratory tests to determine the effect of the product on cancer cells.

Research unit

Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, Laboratory of Experimental Anticancer Therapy

Examination method

These were in vitro tests (performed under laboratory conditions) on five human cancer cell lines: lung cancer, prostate cancer, breast cancer, ovarian cancer and colorectal cancer.

Full report

Summary of tests

The tests showed that the TP2 product has approximately 2–2.5 times higher activity, compared with TP1, in inhibiting cancer cell growth (under laboratory conditions). The higher activity of TP2 is associated with the presence of iron and copper ions in that product.

Results for TP2

The TP2 product was applied directly to tumour cells at various concentrations (dilutions). The number of cells after treatment with the tested products was compared with the number of control cells (not treated with anything) and was determined as a percentage of viable cells, taking the number of control cells as 100%.

Prostate cancer (PC-3 human prostate cancer cells)

Preparat TP2 w najwyższym zastosowanym rozcieńczeniu 1:400 komórki nowotworowe raka prostaty zahamował o ok. 78 % (w warunkach laboratoryjnych), czyli żywych komórek nowotworowych raka prostaty zostało tylko ok. 22 % w porównaniu do komórek kontrolnych.

Colorectal cancer (HT-29 human colon cancer cells)

The TP2 product at the highest dilution used (1:400) inhibited colorectal cancer cells by about 97% (under laboratory conditions), meaning that only about 3% of viable colorectal cancer cells survived, when compared with the control cells.

Ovarian cancer (A2780 human ovarian cancer cells)

The TP2 product inhibited lung cancer and breast cancer cells by about 96%, meaning that only about 4% of viable lung cancer and breast cancer cells survived.

Lung cancer (A549 human lung cancer cells)

The TP2 product at the highest dilution used (1:400) inhibited lung cancer cells by about 96% (under laboratory conditions), meaning that only about 4% of viable lung cancer cells survived, when compared with the control cells.

Breast cancer (MCF-7 human breast cancer cells)

The TP2 product at the highest dilution used (1:400) inhibited breast cancer cells by about 96% (under laboratory conditions), meaning that only about 4% of viable breast cancer cells survived, when compared with the control cells.

Test report 2020

Contact